Strong inhibition of neuronal nitric oxide synthase by the calmodulin antagonist and anti-estrogen drug tamoxifen

Biochemical Pharmacology

Volumn 54, Issue 10, 1997, Pages 1109-1114

  Renodon, Axelle ^a   Boucher, Jean Luc ^a   Sari, Marie Agnes ^a   Delaforge, Marcel ^a   Ouazzani, Jamal ^a   Mansuy, Daniel ^a  

^a CNRS   (France)

Author keywords

Calmodulin; Constitutive nitric oxide synthase; Inhibitor; Peroxynitrite; Tamoxifen

Indexed keywords

ANTIESTROGEN; CALMODULIN; CALMODULIN INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SUPEROXIDE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME INHIBITION; MACROPHAGE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT;

ANIMALS; CALMODULIN; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; MICE; MICE, INBRED C3H; NEURONS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; RATS; TAMOXIFEN;

EID: 0030662115     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00316-X     Document Type: Article

References (39)

1. Jordan VC. Tamoxifen toxicities and drug resistance during the treatment and prevention of breast cancer . Annu Rev Pharmacol Toxicol. 35:1995;195-211.
2. Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 110:1993;507-517.
3. Mansi JL, Smith IE. Endocrine therapy for breast cancer mechanisms and new approaches . Cancer Topics. 7:1989;57-59.
4. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF-7 cells Correlation between binding to estrogen receptor and inhibition of cell growth . Cancer Res. 42:1982;317-323.
5. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 36:1984;245-276.
6. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326:1992;852-862.
7. White INH, DeMatteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57B1/6 mice and human MCL-5 cells. Carcinogenesis. 13:1992;2197-2203.
8. Smith LL, White INH. Chemoprevention of breast cancer by tamoxifen risks and opportunities . Toxicol Lett. 82/83:1995;181-186.
9. Lam HYP. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun. 118:1984;27-32.
10. O'Brien CA, Liskamp RM, Soloman DH, Weinstein IB. Triphenylethylenes a new class of protein kinase C inhibitors . J Natl Cancer Inst. 76:1986;1234-1246.
11. Guliano A, Barrera G, Vacca A, Farina A, Ferretti C, Screpanti J, Dianzani MW, Frati L. Calmodulin antagonism and growth inhibiting activity of triphenylethylene antiestrogen in MCF-7 human breast cancer cells. Cancer Res. 46:1986;6274-6278.
12. Rowlands MG, Parr IB, McCague R, Jarman M, Goddard PM. Variation of the inhibition of calmodulin-dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen Correlations with cytotoxicity . Biochem Pharmacol. 40:1990;283-289.
13. Frankfurt OS, Sugarbaker EV, Robb JA, Villa L. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett. 97:1995;149-154.
14. Edwards KJ, Laughton CA, Neidle S. A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin. J Med Chem. 35:1992;2753-2761.
15. Hardcastle IR, Rowlands MG, Houghton J, Parr IB, Potter GA, Jarman M, Edwards KJ, Laughton CA, Trent JO, Neidle S. Rationally designed analogues of tamoxifen with improved calmodulin antagonism. J Med Chem. 38:1995;241-248.
16. Kerwin JF, Heller J, Heller M. The arginine-nitric oxide pathway a target for new drugs . Med Res Rev. 14:1994;23-74.
17. Kerwin JF, Lancaster JR, Feldman PL. Nitric oxide a new paradigm for second messengers . J Med Chem. 38:1995;4343-4362.
18. Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert N. Nitric oxide synthase isozymes characterization, purification, molecular cloning and functions . Hypertension. 23:1994;1121-1131.
19. Masters BSS, Mcmillan K, Sheta EA, Nishimura JS, Roman LJ, Martasek P. Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO as a cellular signal . FASEB J. 10:1996;552-557.
20. Klatt P, Schmidt K, Uray G, Mayer B. Multiple catalytic functions of brain nitric oxide synthase. J Biol Chem. 268:1993;14781-14787.
21. Abu-Soud H, Feldman PL, Clark P, Stuehr DJ. Electron transfer in the nitric oxide synthases characterization of L-arginine analogs that block heme iron reduction . J Biol Chem. 269:1994;32318-32326.
22. Abu-Soud H, Stuehr DJ. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc Natl Acad Sci USA. 90:1993;10769-10772.
23. 2+/Calmodulin-dependent cytochrome c reductase activity of brain nitric oxide synthase. J Biol Chem. 267:1992;11374-11378.
24. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol. 41:1991;1911-1919.
25. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. Drug Metab Dispos. 21:1993;645-656.
26. Kern L, De Montigny J, Lacroute F. The FUR1 gene of Saccharomyces cerevisiae cloning, structure and expression of wild-type and mutant alleles . Gene. 88:1990;149-157.
27. Truan G, Cullin C, Reisdorf P, Urban P, Pompon D. Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5. Gene. 125:1993;49-55.
28. Urban P, Cullin C, Pompon D. Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells. Biochimie. 72:1990;463-472.
29. Black SM, Ortiz de Montellano PR. Characterization of rat neuronal nitric oxide synthase expressed in Saccharomyces cerevisiae. DNA Cell Biol. 14:1995;789-794.
30. Sari MA, Booker S, Jaouen M, Vadon S, Boucher JL, Pompon D, Mansuy D. Expression in yeast and purification of functional macrophage nitric oxide synthase evidence for cysteine-194 as iron proximal ligand . Biochemistry. 35:1996;7204-7213.
31. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA. 87:1990;682-685.
32. 15N]nitrate in biological fluids. Anal Biochem. 126:1982;131-138.
33. Finter NB. Dye uptake methods for assaying viral cytopathogenicity and their application to interferon assays. J Gen Virol. 5:1969;419-424.
34. Hu J, Lee JH, El-Fakahany EE. Inhibition of neuronal nitric oxide synthase by antipsychotic drugs. Psychopharmacology. 114:1994;161-166.
35. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 72:1995;41-44.
36. Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, Hidaka H, Iguchi A. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun. 214:1995;847-855.
37. Pryor WA, Squadrito GL. The chemistry of peroxynitrite a product from the reaction of nitric oxide with superoxide . Am J Physiol. 268:1995;L699-L722.
38. Tamir S, Tannenbaum SR. The role of nitric oxide (NO) in the carcinogenic process. Biochem Biophys Acta. 1288:1996;F31-F36.
39. Deliconstantinos G, Villiotou V, Stavrides JC, Salemes N, Gogas J. Nitric oxide and peroxynitrite production by human erythrocytes a causative factor of toxic anemia in breast cancer patients . Anticancer Res. 15:1995;1435-1446.